EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 120 filers reported holding EAGLE PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is 0.42 and the average weighting 1.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $7,000 | 0.0% | 113 | -7.4% | 0.00% | – |
Q3 2019 | $7,000 | +250.0% | 122 | +190.5% | 0.00% | – |
Q2 2019 | $2,000 | 0.0% | 42 | 0.0% | 0.00% | – |
Q1 2019 | $2,000 | -33.3% | 42 | -44.0% | 0.00% | – |
Q4 2018 | $3,000 | -70.0% | 75 | -47.2% | 0.00% | – |
Q3 2018 | $10,000 | -94.4% | 142 | -95.8% | 0.00% | -100.0% |
Q2 2018 | $178,000 | 0.0% | 3,399 | 0.0% | 0.00% | 0.0% |
Q1 2018 | $178,000 | -0.6% | 3,399 | +1.5% | 0.00% | 0.0% |
Q4 2017 | $179,000 | -11.8% | 3,349 | 0.0% | 0.00% | 0.0% |
Q3 2017 | $203,000 | -22.2% | 3,349 | +0.9% | 0.00% | -33.3% |
Q2 2017 | $261,000 | -4.7% | 3,318 | +0.5% | 0.00% | 0.0% |
Q1 2017 | $274,000 | +4.6% | 3,300 | 0.0% | 0.00% | -25.0% |
Q4 2016 | $262,000 | +13.4% | 3,300 | 0.0% | 0.00% | +33.3% |
Q3 2016 | $231,000 | +75.0% | 3,300 | -1.5% | 0.00% | +50.0% |
Q2 2016 | $132,000 | +6500.0% | 3,350 | +6600.0% | 0.00% | – |
Q1 2016 | $2,000 | -50.0% | 50 | 0.0% | 0.00% | – |
Q4 2015 | $4,000 | -87.9% | 50 | -87.7% | 0.00% | -100.0% |
Q2 2015 | $33,000 | – | 405 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JW Asset Management, LLC | 475,755 | $25,068,000 | 24.71% |
Hudson Executive Capital LP | 971,000 | $51,162,000 | 15.09% |
Park West Asset Management LLC | 1,051,274 | $55,392,000 | 2.47% |
U S GLOBAL INVESTORS INC | 19,200 | $1,012,000 | 0.62% |
Capital Impact Advisors, LLC | 26,317 | $1,387,000 | 0.57% |
CLARK ESTATES INC/NY | 56,278 | $2,965,000 | 0.47% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 873,131 | $46,005,000 | 0.41% |
ProQuest Associates IV LLC | 6,777 | $357,000 | 0.41% |
Granite Investment Partners, LLC | 114,207 | $6,017,000 | 0.40% |
GLOBEFLEX CAPITAL L P | 30,900 | $1,628,000 | 0.34% |